TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9890612

Group type: EXPERIMENTAL
Intervention: Breast milk from mothers of infants with cow milk allergy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Breast milk from mothers of healthy infants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast milk from mothers with cow milk allergic infants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Breast milk from mothers with healthy infants
Number of subjects: 60
Study: 8994201

Group type: EXPERIMENTAL
Intervention: Subjects with complete callosal defect (one acquired and one congenital)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 1897469

Group type: EXPERIMENTAL
Intervention: High-potassium diet (163 +/- 9 mmol potassium/d) with potassium load (50 mmol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-potassium diet (69 +/- 2 mmol potassium/d) with placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chronic potassium intake
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acute potassium intake
Number of subjects: 8
Study: 7049307

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg on the day of operation and for the following 2 days)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 31487406

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg (T100)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (T200)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Tildrakizumab 100 mg (T100) with placebo (PBO)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Tildrakizumab 200 mg (T200) with placebo (PBO)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) switching to Tildrakizumab 200 mg (ETN/T200)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (T100/T100 or T200/T200)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (T100/T200 or T200/T100)
Number of subjects: 1862
Study: 29756262

Group type: COMPARATOR
Intervention: Reduced serving sizes (by 25%) of alcohol in study 1
Number of subjects: 278

Group type: COMPARATOR
Intervention: Reduced serving sizes (by 28.6-33.3%) of alcohol in study 2
Number of subjects: 278

Group type: COMPARATOR
Intervention: Decreasing the serving size of on-trade alcoholic beverages by 25%
Number of subjects: 278
Study: 29122000

Group type: EXPERIMENTAL
Intervention: Foot-care awareness program for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study: 26711976

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) cystoscopy assisted holmium laser resection (HoLRBt)
Number of subjects: 124

Group type: COMPARATOR
Intervention: White light imaging transurethral resection (WLI-TURBt)
Number of subjects: 124
Study: 24122669

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (A-L)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Amodiaquine-sulfadoxine-pyrimethamine (AQ-SP)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AQ-AS)
Number of subjects: 186
Study: 21615951

Group type: EXPERIMENTAL
Intervention: Problem solving therapy, regular written communication, patient support, cultural assessment, improved access to primary care, risk management strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (treatment as usual)
Number of subjects: 0
Study: 18305265

Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute) in less severe septic shock
Number of subjects: 778

Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute) in less severe septic shock
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute) in more severe septic shock
Number of subjects: 778

Group type: COMPARATOR
Intervention: Norepinephrine (5 to 15 microg per minute) in more severe septic shock
Number of subjects: 778
Study: 15945499

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (appropriate medications)
Number of subjects: 56
Study: 12946968

Group type: EXPERIMENTAL
Intervention: Dynamic muscle training (n = 135)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Relaxation training (n = 128)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Ordinary activity (control group; n = 130)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Dynamic muscle training and relaxation training
Number of subjects: 393
Study: 10784270

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 126
Study: 8578059

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 1800 mg/day)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 2054316

Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2 i.v. push every 21 days pre-operatively, and four additional courses post-operatively (group I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Radical surgery (group II)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Histopathological study of resected specimens after initial chemotherapy
Number of subjects: 71
Study: 6132645

Group type: EXPERIMENTAL
Intervention: Distigmine bromide (Ubretid)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 31039099

Group type: EXPERIMENTAL
Intervention: 7-day recall questions
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: 30-day recall questions
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: 7-day and 30-day recall questions
Number of subjects: 515
Study: 27510741

Group type: COMPARATOR
Intervention: Standard group (brief advance directive form)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Expanded group (brief, expanded, or comprehensive form)
Number of subjects: 316
Study: 26727117

Group type: EXPERIMENTAL
Intervention: REFIT weight loss program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 107
Study: 24892115

Group type: EXPERIMENTAL
Intervention: Professional oral hygiene procedures (1 hour session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (1 hour in the waiting room)
Number of subjects: 40
Study: 22640463

Group type: EXPERIMENTAL
Intervention: E-learning module on leukaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing online resources (Control)
Number of subjects: 0
Study: 19571597

Group type: EXPERIMENTAL
Intervention: sertraline plus atomoxetine
Number of subjects: 276

Group type: COMPARATOR
Intervention: sertraline plus placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 276
Study: 17890427

Group type: EXPERIMENTAL
Intervention: Rosiglitazone therapy for 12 weeks
Number of subjects: 23
Study: 15375799

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: glibenclamide (5 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: voglibose (0.6 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: control group (age-matched healthy subjects, n = 30)
Number of subjects: 45
Study: 11349391

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9133509

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 517

Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 517
Study: 8054013

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 8400
Study: 3615589

Group type: EXPERIMENTAL
Intervention: 0-degree posterior inclination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 15-degree anterior inclination
Number of subjects: 13

Group type: COMPARATOR
Intervention: 30 degrees and 15 degrees posterior inclination
Number of subjects: 13
Study: 28983071

Group type: EXPERIMENTAL
Intervention: Health-oriented language package ('100% organic,' 'all natural' or 'no additives')
Number of subjects: 801

Group type: COMPARATOR
Intervention: Traditional marketing language package ('fine quality,' 'premium blend' or '100% original')
Number of subjects: 801
Study: 27143662

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor monotherapy (PI-monotherapy)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard combination ART (OT group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Symptomatic neurocognitive impairment
Number of subjects: 146
Study: 24716628

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Leptin, PAI-1, hsCRP
Number of subjects: 379
Study: 23741071

Group type: EXPERIMENTAL
Intervention: Ganitumab plus gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20645506

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy with hem-o-lok clips (LAH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy with endo-loop (LAE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic appendectomy (CA)
Number of subjects: 120
Study: 18782697

Group type: EXPERIMENTAL
Intervention: High-thoracic epidural anesthesia plus general anesthesia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Total intravenous anesthesia alone
Number of subjects: 16
Study: 16640102

Group type: EXPERIMENTAL
Intervention: Atazanavir (300 mg once daily) boosted by Ritonavir (100 mg) for 2 weeks, followed by ATV, RTV, and TDF-DF (300 mg) plus optimized NRTIs regimen.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Current HAART regimen (group 1)
Number of subjects: 53
Study: 15022979

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 40
Study: 10949980

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 g cefodizime
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1 g cefodizime
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Skin suction blister fluid (SBF) after cefodizime administration
Number of subjects: 8
Study: 9612148

Group type: EXPERIMENTAL
Intervention: Controlled local delivery of tetracycline HCl
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scaling alone (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups (Test and Control)
Number of subjects: 8
Study: 7935568

Group type: EXPERIMENTAL
Intervention: Fluconazole, 200 mg once a day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral amphotericin B, 800 mg three times a day
Number of subjects: 51
Study: 3741534

Group type: EXPERIMENTAL
Intervention: Metronidazole, 500 mg i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latamoxef (lamoxactam), 2 g i.v.
Number of subjects: 0
Study: 30670009

Group type: EXPERIMENTAL
Intervention: 4 weeks of prehabilitation (group 1, prehab)
Number of subjects: 714

Group type: COMPARATOR
Intervention: No prehabilitation (group 2, no prehab)
Number of subjects: 714
Study: 27993292

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol (5/5 μg)
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol (2.5/5 μg)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: tiotropium 2.5 μg
Number of subjects: 3100

Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 3100

Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 3100
Study: 26169796

Group type: EXPERIMENTAL
Intervention: Pain education and specific training (neck‐shoulder exercises, balance and aerobic training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pain education alone
Number of subjects: 20
Study: 22824853

Group type: EXPERIMENTAL
Intervention: Micropauses (MPs) - 20-second breaks every 20 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control situation (CTL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Without micropauses (WOMP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: With micropauses (WMP)
Number of subjects: 16
Study: 21109234

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20455795

Group type: EXPERIMENTAL
Intervention: Various interventions for depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17477110

Group type: EXPERIMENTAL
Intervention: Drospirenone in combination with 17β‐estradiol
Number of subjects: 0
Study: 15110210

Group type: EXPERIMENTAL
Intervention: Electrocardiographically pulsed spiral computed tomographic protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential acquisition protocol
Number of subjects: 0
Study: 11812391

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (H1 and E1) - solution containing 50 g l(‐1) glucose and 1.34 g l(‐1) NaCl in a volume of water corresponding to 100% of body weight loss
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (H1 and E1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control condition (H0, E0) - solution containing the same quantity of glucose diluted in 100 ml of water
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dehydration conditions (H0 and E0)
Number of subjects: 7
Study: 9922072

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase condom use
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 246
Study: 8044011

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang Granule (type I)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang Granule (type III)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 3128114

Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm single dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 gm doses)
Number of subjects: 90
Study: 8518779

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation via Tracheostomy (TIPPV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation via Nasal Mask (NIPPV)
Number of subjects: 17
Study: 319116

Group type: EXPERIMENTAL
Intervention: Indoprofen (800 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indomethacin (80 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30735919

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus metronomic chemotherapy (capecitabine 500 mg three times per day and cyclophosphamide 50 mg/die)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus metronomic chemotherapy (capecitabine and cyclophosphamide)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 232
Study: 28198498

Group type: COMPARATOR
Intervention: Sugarcane genotypes (varieties RB92579 and RB867515 as controls)
Number of subjects: 12
Study: 26012839

Group type: EXPERIMENTAL
Intervention: Simple line graphs for group-level data
Number of subjects: 70

Group type: COMPARATOR
Intervention: Line graphs with confidence limits or norms for group-level data
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Line graphs for individual-level data
Number of subjects: 70
Study: 22404081

Group type: COMPARATOR
Intervention: Conventional treatment using removable partial dentures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment using resin-bonded bridgework (RBB) to restore to a Shortened Dental Arch (SDA) of 10 occluding contacts
Number of subjects: 44
Study: 22001281

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//PRP∼T (Pentaxim®) booster
Number of subjects: 719

Group type: COMPARATOR
Intervention: Separate vaccines (DTaP, IPV, PRP∼T) booster
Number of subjects: 719
Study: 19858155

Group type: EXPERIMENTAL
Intervention: Pramlintide (maximum dose: 30 microg per meal)
Number of subjects: 10
Study: 16622259

Group type: COMPARATOR
Intervention: docetaxel 43 mg/m2 weekly alone (cohort A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: docetaxel 43 mg/m2 weekly plus etanercept 25 mg subcutaneously twice weekly (cohort B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: docetaxel 52 mg/m2 weekly with etanercept
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: etanercept/docetaxel
Number of subjects: 12
Study: 15642958

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin formulations (Cotecxin, Arenco n.v. Pharmaceutica, Mahidol University)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo model
Number of subjects: 0
Study: 11590630

Group type: EXPERIMENTAL
Intervention: Surrogate endpoint analysis using a joint model for the surrogate and the true endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binary surrogate endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinal endpoints
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analytic context
Number of subjects: 0
Study: 9849452

Group type: EXPERIMENTAL
Intervention: Supportive care plus chemotherapy (carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 48
Study: 7812703

Group type: EXPERIMENTAL
Intervention: Chemotherapy (exact regimen not specified)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Revised model for identifying high-risk patients (including factors such as WHO PS ≥2 and white blood cell count > 10,000/mm3)
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Half doses of drugs at the first cycle (suggested intervention)
Number of subjects: 2196
Study: 2691252

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 97
Study: 31729127

Group type: EXPERIMENTAL
Intervention: Fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Sulphonylurea gliclazide plus other glucose-lowering drugs targeting a glycated hemoglobin value of 6.5% or less
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 30663196

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 279
Study: 28691761

Group type: EXPERIMENTAL
Intervention: Couples communication skills training (CCST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Education comparison intervention
Number of subjects: 32
Study: 25675123

Group type: EXPERIMENTAL
Intervention: Erlotinib (once daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Chemotherapy (3-weekly cycles)
Number of subjects: 86
Study: 23241734

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam-Paracetamol combination
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam and Paracetamol combination
Number of subjects: 90
Study: 21533969

Group type: EXPERIMENTAL
Intervention: Mesh fixation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Mesh nonfixation
Number of subjects: 104
Study: 19040340

Group type: EXPERIMENTAL
Intervention: New drugs and new approaches including response prediction based on sequential (18)FDG‐PET scanning following induction chemotherapy
Number of subjects: 0
Study: 16949590

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 310

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 310
Study: 12930166

Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate (CM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate and Glutamine (CG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 29
Study: 11765879

Group type: EXPERIMENTAL
Intervention: Child Development Review (CDR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Denver II Developmental Screening Test (Denver II)
Number of subjects: 73
Study: 9973775

Group type: EXPERIMENTAL
Intervention: Pommel Horse (PH)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Roman Ring (RR)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Parallel Bar (PB)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Horizontal Bar (HB)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Floor Exercise (FE)
Number of subjects: 5
Study: 8057515

Group type: EXPERIMENTAL
Intervention: Maximized glycemic control (subcutaneous insulin given several times a day or continuously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard glycemic control (subcutaneous insulin given once or twice each day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maximized treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maximized glycemic control
Number of subjects: 48
Study: 3140744

Group type: EXPERIMENTAL
Intervention: L-arginine (25 g/day, n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: L-glycine (43 g/day, n = 14)
Number of subjects: 30
Study: 31513665

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 inhibitor)
Number of subjects: 39

Group type: COMPARATOR
Intervention: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab, golimumab)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (Anakinra and TNFi)
Number of subjects: 39
Study: 29021371

Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS) containing 47 mg potassium iodate/kg and 3.3 mg microencapsulated ferrous fumarate/g (1.1 mg elemental Fe/g)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control iodized salt
Number of subjects: 126
Study: 26643548

Group type: EXPERIMENTAL
Intervention: Regional brain β-amyloid (Aβ) measured with [18F]florbetapir PET
Number of subjects: 128

Group type: COMPARATOR
Intervention: Demographic variables, BMI, and APOE status
Number of subjects: 128
Study: 24631312

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 538